0.420
0.00 (1.16%)
| Penutupan Terdahulu | 0.415 |
| Buka | 0.420 |
| Jumlah Dagangan | 152,374 |
| Purata Dagangan (3B) | 970,739 |
| Modal Pasaran | 9,090,964 |
| Harga / Buku (P/B) | 2.81 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 May 2025 |
| EPS Cair (TTM) | -0.160 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 50.08% |
| Nisbah Semasa (MRQ) | 1.88 |
| Aliran Tunai Operasi (OCF TTM) | -4.76 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.00 M |
| Pulangan Atas Aset (ROA TTM) | -24.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -116.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Advanced Biomed Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
|
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| % Dimiliki oleh Orang Dalam | 78.69% |
| % Dimiliki oleh Institusi | 0.05% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 19 Sep 2025 | Pengumuman | Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |